Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-DOT: DOT for HCV Therapy in Chennai
NCT02541409Phase 2Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Sep 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sofosbuvir in hepatitis C virus infection (2 arms), sponsored by Johns Hopkins Bloomberg School of Public Health. Primary endpoint: HCV Treatment Completion at 24 weeks. Started Sep 2015; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02541409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541409.